On March 31, 2018 Shanghai Huaota Biopharmaceutical reported that its first category I biological product HB002 injection, IND number ‘CXSL1600123’, was approved by the CDE on June 20th 2017 (Press release, Huabo Biopharm, MAR 31, 2018, View Source [SID1234656061]). It marks Huaota’s first innovative biological drug has officially entered the stage of commercial clinical research.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

HB002 is a new type of recombinant human vascular endothelial growth factor receptor-antibody fusion protein ophthalmic injection, mainly used for the treatment of age-related macular degeneration (AMD). The drug is also known as ‘HB002.1T’, It can inhibit vascular endothelial growth as well as tumor activity. Its second indication application is intended to treat bowel cancer and gastric cancer.

the recombinant human vascular endothelial growth factor receptor-antibody fusion protein ophthalmic injection (HB002.1M) will start clinical trial in July 2017.